NEW YORK--(BUSINESS WIRE)--Oct. 27, 2005--Antigenics Inc. (NASDAQ: AGEN) reported results today for the quarter ended September 30, 2005. The company incurred a net loss attributable to common stockholders of $17.5 million, or $0.38 per share, basic and diluted, for the third quarter of 2005, compared with a net loss attributable to common stockholders in the third quarter of 2004 of $18.7 million, or $0.41 per share, basic and diluted. Reflecting continued progress on developing its product candidate portfolio, Antigenics incurred research and development costs of $12.0 million for the quarter ended September 30, 2005, compared with $9.8 million for the quarter ended September 30, 2004. General and administrative expenses decreased to $5.2 million in the quarter ended September 30, 2005, from $6.3 million in the comparable period last year. Prior year operating expenses included a charge for acquired in-process research and development of $2.9 million. Cash, cash equivalents and short-term investments amounted to $77.2 million on September 30, 2005.
